ASNR Study Groups

ASNR members may join any of our Study Groups when joining or renewing membership. Contact for more information.

Co-Chairs: Tammie Benzinger, MD, PhD; Clifford Jack, MD
Vice Chair: Petrice Cogswell, MD, PhD
This group was created to facilitate the exchange of information in the field of Alzheimer’s Disease and Dementia, with a specific interest in sharing information about the diagnosis, treatment, and research of amyloid-related imaging abnormalities (ARIA).

Co-Chairs: Bruce Wasserman, MD; David Saloner, MD
The goal of this study group is to advance our understanding of cerebrovascular diseases by developing and support vessel wall imaging protocols and clinical/translational studies. Objectives include:

  • Develop uniform protocols for clinical implementation and reimbursement.
  • Stimulate research in the field, including multicenter investigations of the pathophysiology and risk factors of neurovascular disease.
  • Attract people with similar interests in vessel wall imaging from around the world.
  • Promote education and teaching mechanisms in the field, and present a unified voice for achieving vendor support for protocol development.

Co-Chairs: Christopher Whitlow, MD; Jason Druzgal, MD
The goal of this study group is to facilitate the exchange of information and knowledge amongst experts and foster collaborative research in functional and diffusion MRI.

Co-Chairs: Ramon Barajas Jr., MD; Jana Ivanidze, MD, PhD
Formerly the Imaging Genomics and Radiomics Study Group. This study group focuses on the application of PET-guided diagnosis and treatment of primary and metastatic brain tumors, attempting to identify further areas of exploration and multi-society collaboration for the establishment of consensus imaging guidelines, novel translational radiotracer development, and reimbursement advocacy; with a patient centered emphasis.

Objectives include:

  • Connect study group members with current evidence for clinical utility of validated radiotracers and opportunities for improved brain tumor extent delineation, treatment planning and response assessment.
  • Leverage member knowledge and expertise toward translational advancement of novel radiotracers.
  • Provide current evidence and clinical limitations of theranostic approaches with an emphasis on collaborative multi-societal drafting of multi-specialty consensus guidelines regarding applications of PET in Neuro-Oncology.
  • Undertake reimbursement advocacy for clinically useful PET radiotracers and theranostic agents.